Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
Lovell
M C
MC
Hunter & Walsh, Boston, Massachussetts, USA.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D001086:Arabinofuranosyluracil / Q000009:adverse effects / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic / Q000009:adverse effects / Q000331:legislation & jurisprudence / Q000401:mortality; D017277:Drug Approval / Q000331:legislation & jurisprudence; D015507:Drugs, Investigational / Q000009:adverse effects; D006291:Health Policy; D006801:Humans; D007880:Legislation, Drug; D014481:United States; D014486:United States Food and Drug Administration / Q000458:organization & administration
D015507:Drugs, Investigational; D001086:Arabinofuranosyluracil